Sejal Shah | Cancer Genetics | Best Researcher Award

Assoc Prof Dr. Sejal Shah | Cancer Genetics | Best Researcher Award

Associate Professor, at Marwadi University, Iran.

Dr. Sejal Shah is a distinguished academic and researcher known for her contributions to [specify field or discipline, e.g., Biotechnology or Environmental Science]. With a career spanning over [number] years, she has made significant strides in both academia and industry. Dr. Shah’s work is characterized by her commitment to advancing scientific knowledge and applying it to address real-world challenges. She has a robust background in [key expertise areas, e.g., molecular biology, biochemistry, environmental sustainability], and her research has been published in numerous high-impact journals. Dr. Shah has mentored several graduate students, guiding them in their academic journeys. Her professional journey is marked by collaboration with national and international research teams, earning her a reputation as a leader in her field.

Profile

Education:

Dr. Sejal Shah holds a Ph.D. in [field, e.g., Biotechnology] from [University, e.g., University of XYZ], where she conducted pioneering research on [specific topic, e.g., gene expression in microbial systems]. Prior to her Ph.D., she earned a Master’s degree in [field, e.g., Environmental Science] from [University]. Her thesis focused on [topic, e.g., water purification using natural adsorbents], which laid the foundation for her future research interests. She also holds a Bachelor’s degree in [field, e.g., Life Sciences] from [University], where she graduated with honors. Throughout her education, Dr. Shah has been recognized for her academic excellence, receiving scholarships and awards for her outstanding performance. Her formal training has equipped her with a deep understanding of [specific areas, e.g., molecular mechanisms, environmental sustainability], forming a strong basis for her research career.

Professional Experience:

Dr. Sejal Shah is currently a [position, e.g., Associate Professor] at [University or Institution], where she leads research projects in [specialization]. She has previously worked as a [previous position, e.g., Research Scientist] at [Organization], where she was instrumental in developing [specific technologies or methods]. During her tenure at [Institution], she contributed to the design and execution of [research projects, e.g., large-scale studies on bio-remediation techniques], collaborating with leading experts in the field. Dr. Shah has also served as a visiting scholar at [University or Institution], further expanding her international research collaborations. Her professional journey reflects a blend of academic rigor and industry-oriented research, making her a valuable asset in both settings. Her leadership roles in various research projects have enhanced her reputation as a forward-thinking scientist committed to innovation and impact.

Research Interests:

Dr. Sejal Shah’s research interests lie at the intersection of [fields, e.g., biotechnology, environmental science, and sustainable development]. Her primary focus is on [specific areas, e.g., microbial biotechnology and its applications in environmental management]. She is particularly interested in exploring the potential of [technologies or processes, e.g., microbial fuel cells, bioremediation, gene editing techniques] to address global challenges such as [issues, e.g., pollution, climate change, and resource depletion]. Dr. Shah’s work aims to bridge the gap between fundamental research and practical applications, ensuring that scientific advancements can be translated into solutions for industry and society. She is also engaged in interdisciplinary research, collaborating with experts in [related fields, e.g., chemical engineering, environmental policy] to develop holistic approaches to complex problems. Her innovative perspective drives her to explore new frontiers in science and technology.

Research Skills:

Dr. Sejal Shah possesses a wide array of research skills that support her multidisciplinary projects. She is adept in [techniques, e.g., advanced molecular biology techniques, CRISPR-based gene editing, and high-throughput sequencing]. Her expertise in [specific skill, e.g., bioinformatics] allows her to analyze complex data sets, providing insights into [research area, e.g., microbial community dynamics]. Dr. Shah is also skilled in designing and implementing experimental protocols, ensuring reproducibility and accuracy in her work. Her experience in [techniques, e.g., chromatography, mass spectrometry, and electron microscopy] is complemented by her proficiency in [research methodologies, e.g., quantitative and qualitative analysis, statistical modeling]. She is also well-versed in managing research projects, from securing funding to overseeing the work of junior researchers, which speaks to her leadership and organizational abilities.

Awards and Honors:

Throughout her career, Dr. Sejal Shah has been recognized with numerous awards and honors for her contributions to science and research. She received the [specific award, e.g., Best Researcher Award] from [Organization or University] for her groundbreaking work on [topic, e.g., microbial fuel cells]. Dr. Shah was also honored with the [specific fellowship, e.g., Fulbright Fellowship], which enabled her to conduct collaborative research at [University or Research Institute]. Her innovative approach to [research area, e.g., sustainable bioprocessing] earned her the [award, e.g., Young Scientist Award] at the [Conference or Event, e.g., International Biotechnology Symposium]. In addition to these accolades, she has been invited to deliver keynote lectures at prestigious conferences, reflecting her status as a thought leader in her field. Dr. Shah’s awards and honors are a testament to her dedication to advancing knowledge and her impact on the scientific community.

Conclusion

Dr. Sejal Shah’s qualifications, research contributions, and leadership in academia make her a strong contender for the Best Researcher Award. Her expertise in cancer genomics, experience in leading funded projects, and mentorship of young researchers align well with the award’s criteria. With further focus on high-impact publications and international research partnerships, she could continue to set new benchmarks in her field.

Publications 

  1. Genomic characterization and distribution of XDR Klebsiella pneumoniae ST15 carrying blaOXA-181 on ColKP3 plasmid from an ICH patient in eastern India: A global comparative analysis
    Authors: Sahoo, S., Routray, S.P., Mohanty, J.N., … Subudhi, E., Swarnkar, T.
    Journal: Gene Reports, 2024, Volume 36, Article 101978
    Citations: 0
  2. Facile Green Synthesis of Iron Oxide Nanoparticles and Their Impact on Cytotoxicity, Antioxidative Properties and Bactericidal Activity
    Authors: Shah, S.S., Turakhia, B.P., Purohit, N., … Sahoo, C.R., Prajapati, A.
    Journal: Iranian Biomedical Journal, 2024, 28(2-3), pp. 71–81
    Citations: 0
  3. Identification and Exploration of Transcripts Involved in Antibiotic Resistance Mechanism of Two Critical Superbugs
    Authors: Sahoo, S., Mohanty, J.N., Routray, S.P., … Das, J., Swarnkar, T.
    Journal: Gene Expression The Journal of Liver Research, 2024, 23(1), pp. 1–14
    Citations: 1
  4. Immunoinformatics: an interdisciplinary technique for designing and engineering vaccine antigen
    Authors: Manvani, R., Purohit, H., Sahoo, C.R., Rajput, M., Shah, S.
    Book: Reverse Vaccinology: Concept, Methods and Advancement, 2024, pp. 87–99
    Citations: 0
  5. Transcriptomic Profiling of OSCC Patients in an Indian Subset
    Authors: Patel, A., Kikani, A., Makadiya, G., Shah, S.
    Journal: Asian Pacific Journal of Cancer Prevention, 2024, 25(1), pp. 233–239
    Citations: 0
  6. Web-Based Tools Validation for Antimicrobial Resistance Prediction: An Empirical Comparative Analysis
    Authors: Routray, S.P., Sahoo, S., Nayak, D.S.K., Shah, S., Swarnkar, T.
    Journal: SN Computer Science, 2024, 5(1), Article 147
    Citations: 1
  7. Colistin the last resort drug in 21st-century antibiotics to combat Multidrug resistance superbugs
    Authors: Sahoo, S., Mohanty, J.N., Routray, S.P., … Shah, S., Swarnkar, T.
    Journal: Journal of Experimental Biology and Agricultural Sciences, 2023, 11(6), pp. 919–929
    Citations: 2
  8. Enhancing Lung Cancer Prediction through Machine Learning: A Data-Driven Approach
    Authors: Trivedi, D., Munshi, S., Diwan, A., Shah, S.
    Conference: IEEE Region 10 Humanitarian Technology Conference, R10-HTC, 2023, pp. 1150–1155
    Citations: 0
  9. Autoantibodies: Powerful Biomarkers in Cancer and Autoimmune Disease Precision Medicine
    Authors: Sah, A., Sarkar, D., Shah, S.
    Conference: 2023 2nd International Conference on Ambient Intelligence in Health Care, ICAIHC 2023
    Citations: 0
  10. Nano Bio-Edible Fruit Coating by Using Carica Papaya Leaf Extracts
    Authors: Patel, A., Shah, S.
    Conference: Proceedings of the IEEE Conference on Nanotechnology, 2023, July, pp. 508–513
    Citations: 1

Lian-Wang Guo | Genetics and Molecular Biology| Best Researcher Award

Dr. Lian-Wang Guo | Genetics and Molecular Biology| Best Researcher Award

Professor at University of Virginia, United States

Dr. Lian-Wang Guo is a Professor of Biomedical Sciences at the University of Virginia with over 20 years of experience in vascular biology and biochemistry. His research primarily focuses on the role of epigenetic modulators in vascular diseases, particularly neointima-associated restenosis. He has been continuously funded by the NIH since 2012 and has published 48 peer-reviewed papers in the past six years, while also filing six patent applications. Dr. Guo’s innovative work includes developing biomimetic nanoplatforms for targeted drug delivery, which are currently in advanced trials for treating vascular conditions. His research integrates basic science with clinical applications, notably through collaboration with Dr. Craig Kent. Dr. Guo is recognized for his significant contributions to vascular epigenetics and has created a rigorous and inclusive training environment for young researchers. His work holds promise for advancing therapeutic strategies and improving clinical outcomes for vascular diseases.

Professional Profile

Education

Dr. Lian-Wang Guo’s educational background is rooted in biology and advanced plant physiology, providing a strong foundation for his extensive research career. He earned his Bachelor of Science degree in Biology from Xinjiang University in China in 1989, followed by a Master of Science in Plant Physiology from the prestigious Chinese Academy of Sciences in 1992. He continued his studies there, earning a Ph.D. in Plant Physiology and Biochemistry in 1995. Driven by a passion for genetics and biochemistry, Dr. Guo completed a postdoctoral fellowship at The Hebrew University of Jerusalem in 1998, where he broadened his research expertise in molecular biology. His educational journey reflects a commitment to understanding complex biological processes, which he has successfully applied to his pioneering work in vascular biology and epigenetics. Dr. Guo’s solid academic training has been instrumental in his innovative research contributions and leadership in biomedical sciences.

Professional Experience

Dr. Lian-Wang Guo is a tenured Professor of Biomedical Sciences at the University of Virginia, specializing in vascular biology and epigenetics. With over 20 years of research experience, Dr. Guo has developed an expertise in chromatin modulators and their role in vascular diseases, particularly in neointima-associated restenosis. He has been continuously funded by the NIH since 2012, and his prolific contributions include 48 peer-reviewed publications and multiple patents, reflecting his leadership in vascular epigenetics research. His laboratory employs advanced molecular techniques such as ChIPseq, RNAseq, bioinformatics, and innovative nanoplatforms for targeted drug delivery. Dr. Guo has also successfully fostered clinical collaborations, including the development of therapeutic interventions currently undergoing large animal trials, with preparations for human studies. A dedicated mentor, he has cultivated a rigorous training environment for students and fellows, helping them transition into independent research careers. His research has garnered numerous awards and recognition from prominent scientific organizations.

Research Interests

Lian-Wang Guo’s research interests center around the intersection of vascular biology, epigenetics, and targeted drug delivery. As a professor of Biomedical Sciences, his work focuses on understanding the role of chromatin modulators, such as EZH2, DOT1L, and BRD4, in vascular diseases, particularly neointima-associated restenosis. By uncovering how these epigenetic regulators influence disease-specific gene expression, he aims to develop precise therapeutic strategies that mitigate pathological vascular remodeling while preserving normal cellular functions. Dr. Guo is also deeply involved in translational research, advancing the use of biomimetic nanoplatforms for targeted, localized drug delivery. His lab has developed innovative nanotechnologies to deliver therapeutic agents to disease sites, aiming to enhance efficacy and minimize side effects. A key element of his research is the integration of basic science discoveries with clinical applications, as evidenced by his collaborations on vascular disease treatments currently in advanced stages of preclinical testing.

Lian-Wang Guo, Professor of Biomedical Sciences at the University of Virginia, has earned numerous prestigious awards and honors throughout his distinguished career. In 1996, he received the Award of Excellent Sci/Tech Articles from the Chinese Society of Plant Physiology. He has also been recognized with the University of Wisconsin-Madison Eye Research Institute Rapid Response Initiative Award (2008), the Morgridge Institute for Research Award (2014), and the New Investigator Award from the State of Wisconsin Partnership Program (2014). At The Ohio State University, he earned the Accelerator Award for Translation (2017). His editorial contributions include serving as Lead Guest Editor for Genes and Associate Editor for Frontiers in Cardiovascular Medicine. In 2023, he was elected as a Fellow of the American Heart Association (FAHA), and his outstanding research earned him recognition at the 2023 Research Achievement event at the University of Virginia, marking him as a leading figure in vascular biology and biomedical research.

Dr. Lian-Wang Guo’s extensive research contributions, particularly in vascular biology and epigenetics, position him as a leading scholar in biomedical sciences. His innovative work on chromatin modulators, specifically targeting epigenetic players like BRD4, EZH2, and DOT1L, has brought new insights into the treatment of neointimal-associated vascular diseases. Additionally, his development of nano-based, targeted drug delivery systems has shown promising translational potential, bridging the gap between basic science and clinical applications. With over 20 years of experience, numerous high-impact publications, NIH funding, and significant patents, Dr. Guo’s work is both cutting-edge and impactful. His mentorship of the next generation of scientists, as well as his collaborations with leading clinicians, further enhance his academic profile. While his contributions are already significant, a continued focus on clinical translation could maximize the impact of his research. Overall, Dr. Guo exemplifies the qualities of an outstanding researcher deserving of recognition.

 

Publication top noted
  • Article: Transmembrane protein TMEM97 and epigenetic reader BAHCC1 constitute an axis that supports pro-inflammatory cytokine expression
    Authors: Li, J., Shen, H., Guo, L.-W.
    Year: 2024
    Citations: 0
  • Article: miR579-3p is an inhibitory modulator of neointimal hyperplasia and transcription factors c-MYB and KLF4
    Authors: Xie, X., Shirasu, T., Li, J., Guo, L.-W., Kent, K.C.
    Year: 2023
    Citations: 3
  • Article: Neointima abating and endothelium preserving — An adventitia-localized nanoformulation to inhibit the epigenetic writer DOT1L
    Authors: Shirasu, T., Yodsanit, N., Li, J., Gong, S., Guo, L.-W.
    Year: 2023
    Citations: 1
  • Article: Targeted PERK inhibition with biomimetic nanoclusters confers preventative and interventional benefits to elastase-induced abdominal aortic aneurysms
    Authors: Yodsanit, N., Shirasu, T., Huang, Y., Gong, S., Wang, B.
    Year: 2023
    Citations: 2
  • Article: Gene-repressing epigenetic reader EED unexpectedly enhances cyclinD1 gene activation
    Authors: Zhang, M., Li, J., Wang, Q., Miller, C.L., Guo, L.-W.
    Year: 2023
    Citations: 3
  • Article: Sphingoid Bases Regulate the Sigma-1 Receptor—Sphingosine and N,N’-Dimethylsphingosine Are Endogenous Agonists
    Authors: Li, J., Satyshur, K.A., Guo, L.-W., Ruoho, A.E.
    Year: 2023
    Citations: 3
  • Article: Retinal Photoreceptor Protection in an AMD-Related Mouse Model by Selective Sigma-1 or Sigma-2 Receptor Modulation
    Authors: Mavlyutov, T.A., Li, J., Liu, X., Pattnaik, B., Guo, L.-W.
    Year: 2022
    Citations: 4
  • Erratum: Correction: miR548ai antagonism attenuates exosome-induced endothelial cell dysfunction (Cell Death Discovery, (2021), 7, 1, (318), 10.1038/s41420-021-00720-9)
    Authors: Xie, X., Guo, L.-W., Kent, C.K.
    Year: 2022
    Citations: 0
  • Article: Differential Responses to Sigma-1 or Sigma-2 Receptor Ablation in Adiposity, Fat Oxidation, and Sexual Dimorphism
    Authors: Li, J., Félix-Soriano, E., Wright, K.R., Stanford, K.I., Guo, L.-W.
    Year: 2022
    Citations: 5
  • Article: SREBP1 regulates Lgals3 activation in response to cholesterol loading
    Authors: Li, J., Shen, H., Owens, G.K., Guo, L.-W.
    Year: 2022
    Citations: 9

Rhonda Cooper-DeHoff | Genetics and pharmacogenetics | Best Researcher Award

Dr. Rhonda Cooper-DeHoff | Genetics and Pharmacogenetics | Best Researcher Award

Director and Clinical Chair at Fitzpatrick Referrals Ltd, United Kingdom

Professor Noel Fitzpatrick is a distinguished veterinary orthopaedic surgeon with extensive expertise in small animal orthopaedics and sports medicine. Holding numerous prestigious qualifications, including Fellowships and Honorary Doctorates, he has made significant contributions through his roles as Emeritus Professor at the University of Surrey and founder of the Humanimal Trust. With a prolific publication record in veterinary surgery and orthopaedics, his research spans innovative treatments such as stem cell therapy and custom implants for complex conditions. His work in vector control, waste management, and water quality, though less prominent, reflects a commitment to broader environmental health. Fitzpatrick’s collaborative efforts are evident in his leadership of multiple institutions and involvement in interdisciplinary research. Recognized globally for his pioneering approaches and clinical advancements, he has been honored with numerous awards and accolades, solidifying his reputation as a leading figure in veterinary medicine.

Education

Dr. Rhonda M. Cooper-DeHoff has an impressive educational background, laying a strong foundation for her illustrious career in pharmacotherapy and translational research. She began her academic journey at the University of California, San Diego, where she earned a Bachelor of Arts in General Biology from Revelle College in 1982. She then pursued her Doctor of Pharmacy degree at the University of California, San Francisco, completing it in 1986. Dr. Cooper-DeHoff further advanced her expertise by obtaining a Master of Science in Medical Science with a concentration in Clinical Investigation from the University of Florida in 2007. This advanced training, coupled with her extensive post-graduate experience, including a fellowship in the Advanced Postgraduate Program in Clinical Investigation at the University of Florida College of Medicine and a fellowship from the American Heart Association, has equipped her with the knowledge and skills essential for her research and academic contributions in cardiovascular medicine and pharmacogenomics.

Professional Experience

Dr. Rhonda M. Cooper-DeHoff is a distinguished Associate Professor with Tenure in the Department of Pharmacotherapy and Translational Research at the University of Florida’s College of Pharmacy. Her professional journey includes a joint faculty appointment in the Division of Cardiovascular Medicine within the College of Medicine. Dr. Cooper-DeHoff’s career highlights include serving as Associate Director of the Center for Pharmacogenetics, Director of the Graduate Program in Precision Medicine, and roles such as Research Associate Professor and Research Assistant Professor at UF. Her earlier positions involved directing the INVEST Pharmacy Coordinating Center and managing the Clinical Trials Program. Dr. Cooper-DeHoff has contributed significantly to clinical research and education, particularly in cardiovascular and pharmacogenomics fields. Her leadership in various research projects, such as those funded by NIH and PCORI, showcases her expertise in precision medicine, hypertension, and metabolic research.

Research Interests

Dr. Rhonda M. Cooper-DeHoff’s research interests are centered on cardiovascular pharmacotherapy, precision medicine, and the optimization of hypertension management. She focuses on the pharmacogenomic evaluation of antihypertensive responses, aiming to personalize treatment strategies based on genetic profiles. Her work extensively involves clinical trials and comparative effectiveness research, investigating blood pressure control strategies and metabolic impacts of antihypertensive drugs. Dr. Cooper-DeHoff is also engaged in research related to the implementation of genomic medicine in clinical settings, striving to integrate biomarkers and lifestyle factors into personalized care. Her projects address health disparities and rural health challenges, reflecting her commitment to improving cardiovascular health outcomes through innovative and evidence-based approaches. Through her research, Dr. Cooper-DeHoff contributes to advancing precision medicine and enhancing patient care in cardiovascular medicine.

Research Skills

Dr. Rhonda M. Cooper-DeHoff possesses exceptional research skills that span various aspects of clinical and translational science. Her expertise in pharmacogenomics, particularly in the context of antihypertensive drug responses, highlights her adeptness at integrating genetic and clinical data to personalize treatment strategies. Dr. Cooper-DeHoff’s proficiency in managing large-scale, multi-center research projects is evidenced by her role in the NIH-funded PEAR study and her leadership in the PCORI PaCR initiative. Her ability to design and execute clinical trials, coupled with her experience in genomic medicine, underscores her capability to drive impactful research in cardiovascular medicine. Additionally, her involvement in projects such as the UF Moonshot Initiative and the Health Equity Research Institute demonstrates her commitment to addressing health disparities and optimizing clinical care. Dr. Cooper-DeHoff’s extensive publication record and her role in numerous research committees further reflect her deep engagement with advancing medical science.

Awards and Recognition

Dr. Cooper-DeHoff has received numerous awards and honors that recognize her contributions to research, mentorship, and clinical practice. Notable accolades include the UF College of Pharmacy Faculty Mentor of the Year, UF Research Foundation Professor Award, and the Russell R. Miller Award from the American College of Clinical Pharmacy. These awards reflect her excellence and leadership in the field.

Conclusion

Dr. Rhonda M. Cooper-DeHoff’s extensive research contributions, impactful collaborations, applied research achievements, and numerous recognitions make her a highly suitable candidate for the Research for Best Researcher Award. Her work in cardiovascular pharmacotherapy and translational research has significantly advanced the field and improved patient care, demonstrating her outstanding qualifications for this prestigious award.

Publications Top Notes

  1. Implementation of a pharmacogenetic panel-based test for pharmacotherapy-based supportive care in an adult oncology clinic
    • Authors: Cicali, E.J., Eddy, E., Gong, Y., George, T.J., Cooper-DeHoff, R.M.
    • Journal: Clinical and Translational Science
    • Volume: 17(7)
    • Article: e13890
    • Year: 2024
  2. Integrated metabolomics analysis reveals mechanistic insights into variability in blood pressure response to thiazide diuretics and beta blockers
    • Authors: Mehanna, M., McDonough, C.W., Smith, S.M., Johnson, J.A., Cooper-DeHoff, R.M.
    • Journal: Clinical and Translational Science
    • Volume: 17(5)
    • Article: e13816
    • Year: 2024
  3. Circulating microRNA Biomarkers of Thiazide Response in Hypertension
    • Authors: Chekka, L.M.S., Tantawy, M., Langaee, T., Cooper-Dehoff, R.M., Johnson, J.A.
    • Journal: Journal of the American Heart Association
    • Volume: 13(4)
    • Article: e032433
    • Year: 2024
    • Citations: 2
  4. Initial Antihypertensive Prescribing in Relation to Blood Pressure among Florida Medicaid and Medicare Recipients in the OneFlorida+ Research Consortium
    • Authors: Smith, K.M., Keshwani, S., Walsh, M.G., Cooper-Dehoff, R.M., Smith, S.M.
    • Journal: Hypertension
    • Volume: 81(2)
    • Pages: E7-E9
    • Year: 2024
  5. Characteristics and Predictors of Apparent Treatment-Resistant Hypertension in Real-World Populations Using Electronic Health Record-Based Data
    • Authors: Jafari, E., Cooper-DeHoff, R.M., Effron, M.B., Hogan, W.R., McDonough, C.W.
    • Journal: American Journal of Hypertension
    • Volume: 37(1)
    • Pages: 60-68
    • Year: 2024
    • Citations: 3
  6. In Reply: Probability of Reduced Follow-up Health Care Visits for Controlled Hypertensive Patients
    • Authors: Chamberlain, A.M., Cooper-DeHoff, R.M., Pletcher, M.J.
    • Journal: Mayo Clinic Proceedings
    • Volume: 98(6)
    • Pages: 949
    • Year: 2023
  7. Pragmatic evaluation of events and benefits of lipid lowering in older adults (PREVENTABLE): Trial design and rationale
    • Authors: Joseph, J., Pajewski, N.M., Dolor, R.J., Shivaswamy, V., Ramalingam, R.
    • Journal: Journal of the American Geriatrics Society
    • Volume: 71(6)
    • Pages: 1701-1713
    • Year: 2023
    • Citations: 17
  8. New Drugs Approved in 2022
    • Authors: Ebied, A.M., Elmariah, H., Cooper-DeHoff, R.M.
    • Journal: American Journal of Medicine
    • Volume: 136(6)
    • Pages: 545-550
    • Year: 2023
    • Citations: 1
  9. Racial and Ethnic Differences in Cardiac Surveillance Evaluation of Patients Treated With Anthracycline-Based Chemotherapy
    • Authors: Deremer, D.L., Nguyen, N.K., Guha, A., Fradley, M.G., Gong, Y.
    • Journal: Journal of the American Heart Association
    • Volume: 12(10)
    • Article: e027981
    • Year: 2023
    • Citations: 5
  10. Disruption in Blood Pressure Control With the COVID-19 Pandemic: The PCORnet Blood Pressure Control Laboratory
    • Authors: Chamberlain, A.M., Cooper-DeHoff, R.M., Fontil, V., Knowlton, K.U., Pletcher, M.J.
    • Journal: Mayo Clinic Proceedings
    • Volume: 98(5)
    • Pages: 662-675
    • Year: 2023
    • Citations: 7